Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (710 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Dietary starch and related high-molecular carbohydrate incapable of enzymatic hydrolysis in the small intestine and instead ferments in the colon, producing short-chain fatty acids by-products.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Where it fits in the MeSH classification
- Broader topics
- Starch; Dietary Fiber
Related concepts
- Small Intestine
- Colon
- Short-Chain Fatty Acids
Research landscape
PubMed indexes 468 records tagged with the MeSH heading “Resistant Starch” (counts retrieved 2026-10-31). 460 of them (98.3%) were published from 2020 onward, and the busiest period so far is 2020 onward with 460 records.
Reviews account for 66 records (14.1%) and meta-analyses for 11. Randomized controlled trials number 39 (8.3%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.
Show the data
| Period | Records |
|---|---|
| through 1999 | 0 |
| 2000-2009 | 0 |
| 2010-2019 | 16 |
| 2020 onward | 460 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 66 | 14.1% |
| Meta-analyses | 11 | 2.4% |
| Randomized controlled trials | 39 | 8.3% |
Method: PubMed query "Resistant Starch"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in anatomy and physiology
Anatomy describes how body structures are built and physiology describes how they normally work, so most findings here are descriptive or mechanistic rather than evidence about treatment. Much of what is known comes from dissection, imaging, tissue studies and experiments in animals, and measurements in healthy volunteers can differ from those in people with disease or at different ages. Normal ranges vary between individuals and populations. Check whether a result was measured in people or in another species, the age and health of the participants, and the method used.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Resistant starch, microbiome, and precision modulation [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Resistant starch, microbiome, and precision modulation.
- Closing excerpt
- The purpose of this review is to detail i) the heterogeneity of resistant starches, ii) how resistant starch is sequentially degraded and fermented by specialized gut microbes, and iii) how resistant starch interventions yield variable effects on the gut microbiome.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (119 words)
Resistant starch, microbiome, and precision modulation. Mounting evidence has positioned the gut microbiome as a nexus of health. Modulating its phylogenetic composition and function has become an attractive therapeutic prospect. Resistant starches (granular amylase-resistant α-glycans) are available as physicochemically and morphologically distinguishable products. Attempts to leverage resistant starch as microbiome-modifying interventions in clinical studies have yielded remarkable inter-individual variation. Consequently, their utility as a potential therapy likely depends predominantly on the selected resistant starch and the subject's baseline microbiome. The purpose of this review is to detail i) the heterogeneity of resistant starches, ii) how resistant starch is sequentially degraded and fermented by specialized gut microbes, and iii) how resistant starch interventions yield variable effects on the gut microbiome.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34275431 · DOI · PMC8288039
Dietary type 2 resistant starch improves systemic inflammation and intestinal permeability by modulating microbiota and metabolites in aged mice on high-fat diet [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Type 2 resistant starch (RS2) is a fermentable dietary fiber conferring health benefits.
- Closing excerpt
- These findings demonstrate that RS2 can reverse weight gain, hepatic steatosis, inflammation, and increased intestinal permeability in aged mice on high-fat diet mediated by changes in gut microbiome and metabolites.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (200 words)
Type 2 resistant starch (RS2) is a fermentable dietary fiber conferring health benefits. We investigated the effects of RS2 on host, gut microbiota, and metabolites in aged mice on high-fat diet. In eighteen-month old mice randomly assigned to control, high-fat (HF), or high-fat+20% RS2 (HFRS) diet for 16 weeks, RS2 reversed the weight gain and hepatic steatosis induced by high-fat diet. Serum and fecal LPS, colonic IL-2 and hepatic IL-4 mRNA expressions decreased while colonic mucin 2 mRNA and protein expressions increased in the HFRS compared to the HF and the control group. 16s rRNA sequencing of fecal microbial DNA demonstrated that RS2 decreased the abundance of pathogen taxa associated with obesity, inflammation, and aging including Desulfovibrio (Proteobacteria phylum), Ruminiclostridium 9, Lachnoclostridium, Helicobacteria, Oscillibacter, Alistipes, Peptococcus, and Rikenella. Additionally, RS2 increased the colonic butyric acid by 2.6-fold while decreasing the isobutyric and isovaleric acid levels by half compared to the HF group. Functional analyses based on Clusters of Orthologous Groups showed that RS2 increased carbohydrate while decreasing amino acid metabolism. These findings demonstrate that RS2 can reverse weight gain, hepatic steatosis, inflammation, and increased intestinal permeability in aged mice on high-fat diet mediated by changes in gut microbiome and metabolites.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32452830 · DOI · PMC7288951
Resistant Starch Type 2 from Wheat Reduces Postprandial Glycemic Response with Concurrent Alterations in Gut Microbiota Composition [3]
Abstract reading summary — source excerpts
- Opening excerpt
- The majority of research on the physiological effects of dietary resistant starch type 2 (RS2) has focused on sources derived from high-amylose maize.
- Closing excerpt
- These effects show that RS2-enriched wheat consumption results in a reduction in postprandial glycemia, altered gut microbial composition, and increased fermentation activity relative to wild-type wheat.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (193 words)
The majority of research on the physiological effects of dietary resistant starch type 2 (RS2) has focused on sources derived from high-amylose maize. In this study, we conduct a double-blind, randomized, placebo-controlled, crossover trial investigating the effects of RS2 from wheat on glycemic response, an important indicator of metabolic health, and the gut microbiota. Overall, consumption of RS2-enriched wheat rolls for one week resulted in reduced postprandial glucose and insulin responses relative to conventional wheat when participants were provided with a standard breakfast meal containing the respective treatment rolls (RS2-enriched or conventional wheat). This was accompanied by an increase in the proportions of bacterial taxa Ruminococcus and Gemmiger in the fecal contents, reflecting the composition in the distal intestine. Additionally, fasting breath hydrogen and methane were increased during RS2-enriched wheat consumption. However, although changes in fecal short-chain fatty acid (SCFA) concentrations were not significant between control and RS-enriched wheat roll consumption, butyrate and total SCFAs were positively correlated with relative abundance of Faecalibacterium, Ruminoccocus, Roseburia, and Barnesiellaceae. These effects show that RS2-enriched wheat consumption results in a reduction in postprandial glycemia, altered gut microbial composition, and increased fermentation activity relative to wild-type wheat.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33671147 · DOI · PMC7922998
Resistant Starch in MASLD: Microbial Ecology, Response Heterogeneity and the Path to Precision Nutrition [4]
Abstract reading summary — source excerpts
- Opening excerpt
- Resistant starch (RS) links a modifiable dietary exposure to microbial metabolism and hepatic health in metabolic dysfunction-associated steatotic liver disease (MASLD).
- Closing excerpt
- Independent replication, reproducible functional measurements and marker-stratified trials can establish whether measuring microbial ecology improves nutritional choices alongside standard MASLD care.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (198 words)
Resistant starch (RS) links a modifiable dietary exposure to microbial metabolism and hepatic health in metabolic dysfunction-associated steatotic liver disease (MASLD). A four-month randomized trial of 40 g/day high-amylose maize RS type 2 (HAM-RS2) reduced liver fat, while linked cohort analyses identified substantial variation in response. International trials in other metabolic populations reported null hepatic-fat effects, bringing population and nutritional context into focus. This critical narrative review examines the ecological basis of response variation and its implications for precision nutrition. Three interacting determinants organize the evidence: the preparation consumed, the functional capacity of the recipient microbiota and the host environment in which fermentation occurs. Substrate accessibility, primary degradation and microbial cross-feeding shape the metabolites available to the host. Disease-specific transfer and perturbation experiments support microbial amino-acid and inflammatory pathways; short-chain fatty acid (SCFA) metabolism, bile-acid handling and lipid absorption provide additional candidate links to hepatic response. Quantitative comparisons place RS alongside effective dietary and lifestyle interventions. We connect this framework to a concrete HAM-RS2 research regimen and a staged path from response prediction to comparative treatment benefit. Independent replication, reproducible functional measurements and marker-stratified trials can establish whether measuring microbial ecology improves nutritional choices alongside standard MASLD care.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 42942965 · DOI · PMC13708279
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article The preparation, formation, fermentability, and applications of resistant starch [5]
- Research article Health beneficial effects of resistant starch on diabetes and obesity via regulation of gut microbiota: a review [6]
- Research article Conserved and variable responses of the gut microbiome to resistant starch type 2 [7]
- Research article Synthesis and Functions of Resistant Starch [8]
- Research article Prebiotic Potential of Dietary Beans and Pulses and Their Resistant Starch for Aging-Associated Gut and Metabolic Health [9]
- Research article The Potential Roles of Probiotics, Resistant Starch, and Resistant Proteins in Ameliorating Inflammation during Aging (Inflammaging) [10]
References
- Dobranowski PA, Stintzi A. Resistant starch, microbiome, and precision modulation. . 2021. PMID 34275431 · DOI · PMC8288039
- Zhang Y, Chen L, Hu M, Kim JJ, Lin R, Xu J, et al.. Dietary type 2 resistant starch improves systemic inflammation and intestinal permeability by modulating microbiota and metabolites in aged mice on high-fat diet. . 2020. PMID 32452830 · DOI · PMC7288951
- Hughes RL, Horn WH, Finnegan P, Newman JW, Marco ML, Keim NL, et al.. Resistant Starch Type 2 from Wheat Reduces Postprandial Glycemic Response with Concurrent Alterations in Gut Microbiota Composition. . 2021. PMID 33671147 · DOI · PMC7922998
- Xu Z, Liu Y, Wu H, Xu H, Zheng L. Resistant Starch in MASLD: Microbial Ecology, Response Heterogeneity and the Path to Precision Nutrition. . 2026. PMID 42942965 · DOI · PMC13708279
- Jiang F, Du C, Jiang W, Wang L, Du SK. The preparation, formation, fermentability, and applications of resistant starch. Int J Biol Macromol. 2020. PMID 31739041 · DOI
- Liu H, Zhang M, Ma Q, Tian B, Nie C, Chen Z, et al.. Health beneficial effects of resistant starch on diabetes and obesity via regulation of gut microbiota: a review. Food Funct. 2020. PMID 32602874 · DOI
- Bendiks ZA, Knudsen KEB, Keenan MJ, Marco ML. Conserved and variable responses of the gut microbiome to resistant starch type 2. Nutr Res. 2020. PMID 32251948 · DOI · PMC7295659
- Wang Z, Wang S, Xu Q, Kong Q, Li F, Lu L, et al.. Synthesis and Functions of Resistant Starch. Adv Nutr. 2023. PMID 37276960 · DOI · PMC10509415
- Kadyan S, Sharma A, Arjmandi BH, Singh P, Nagpal R. Prebiotic Potential of Dietary Beans and Pulses and Their Resistant Starch for Aging-Associated Gut and Metabolic Health. Nutrients. 2022. PMID 35565693 · DOI · PMC9100130
- Warman DJ, Jia H, Kato H. The Potential Roles of Probiotics, Resistant Starch, and Resistant Proteins in Ameliorating Inflammation during Aging (Inflammaging). Nutrients. 2022. PMID 35215397 · DOI · PMC8879781
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.